昭衍新药实控人之一周志文计划减持不超近2%公司股份

财中社
Dec 29, 2025

  12月29日,昭衍新药(603127/06127)发布公告,实际控制人之一周志文因自身资金需求,计划自2026年1月22日至2026年4月21日,通过集中竞价和大宗交易方式减持不超过1498万股,占公司总股本的1.99873%。

  2025年前三季度,昭衍新药实现收入9.85亿元,归母净利润8071万元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10